Sarolaner
Clinical data | |
---|---|
Trade names | Simparica |
Other names | PF-6450567 |
ATCvet code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.234.000 |
Chemical and physical data | |
Formula | C23H18Cl2F4N2O5S |
Molar mass | 581.36 g·mol−1 |
3D model (JSmol) | |
| |
|
Sarolaner, sold under the brand name Simparica, is an ectoparasiticide veterinary medication for the treatment of flea and tick infestations in dogs.[2][3] It is also used off-label to control sarcoptic mange and demodectic mange.[3]
Sarolaner is also a component of the combination drug Simparica Trio, which contains sarolaner, moxidectin, and pyrantel.[4] It is used for prevention of heartworm disease caused by Dirofilaria immitis; treat and prevent flea infestations; treat and control tick infestations with the lone star tick, Gulf Coast tick, American dog tick, black-legged tick, and brown dog tick; and treat and control roundworm and adult hookworm infections.[5]
Sarolaner is also an ingredient in feline combination antiparasitic Revolution Plus (or Stronghold Plus[6]), which contains sarolaner and selamectin and is used for prevention of sarcoptic mange, feline hookworms, feline roundworms, ear mites, and heartworms, as well as treating and preventing fleas and ticks.[7]
References
- ^ "Simparica". U.S. Food and Drug Administration (FDA). Retrieved 12 December 2022.
- ^ McTier TL, Chubb N, Curtis MP, Hedges L, Inskeep GA, Knauer CS, et al. (May 2016). "Discovery of sarolaner: A novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs" (PDF). Veterinary Parasitology. 222: 3–11. doi:10.1016/j.vetpar.2016.02.019. PMID 26961590.
- ^ a b Gollakner R. "Sarolaner". vcahospitals.com. VCA Hospitals. Retrieved 26 June 2021.
- ^ "Simparica Trio". U.S. Food and Drug Administration (FDA). Retrieved 12 December 2022.
- ^ "FDA Approves Simparica Trio, a Combination Drug for Heartworm and Other Parasites". U.S. Food and Drug Administration (FDA). 2 March 2020. Retrieved 26 June 2021.
- ^ "Stronghold Plus". European Medicines Agency. Retrieved 12 December 2022.
- ^ "Revolution Plus". U.S. Food and Drug Administration (FDA). Retrieved 12 December 2022.
External links
- "Sarolaner". Drug Information Portal. U.S. National Library of Medicine.